Inficure Bio, based in Umeå in northern Sweden, has recently been granted a patent in the United States for its unique preclinical model. At the same time a study describing the basics of the model has been accepted for publication in respected online journal Scientific Reports.
A new AI solution for sustainable production is to be tested at Diamyd Medical's vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden.
Umeå Biotech Incubator (UBI) has strengthened its board with the appointment of respected business profiles Anette Nordvall, named Sweden's most powerful tech investor by DI Digital, and Camilla Huse Bondesson, who has extensive experience of marketing, sales and business development in the life science industry.
At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson's business law expertise entails a strengthening of the Board and is an important component for the company's continued successful development.
Umeå-based life science company Inficure Bio is one of three companies from northern Sweden chosen to present their business cases at ‘Mötesplats Stockholm – The Great Northern Capital Connect’ in early 2021.
Prediktera from Umeå in northern Sweden has made the list of Europe's most dynamic Artificial Intelligence (AI) startups. “This increases our visibility and opportunities to find partners, employees and customers in Europe and around the world,” says Andreas Vidman, CEO of Prediktera.
Umeå Biotech Incubator (UBI) is one of the hosts of the Swedish Life Science Investor Meeting (24-25th November), a digital event that will bring biotech companies and potential international investors together.